TN2013000027A1 - - 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms - Google Patents
- 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid formsInfo
- Publication number
- TN2013000027A1 TN2013000027A1 TNP2013000027A TN2013000027A TN2013000027A1 TN 2013000027 A1 TN2013000027 A1 TN 2013000027A1 TN P2013000027 A TNP2013000027 A TN P2013000027A TN 2013000027 A TN2013000027 A TN 2013000027A TN 2013000027 A1 TN2013000027 A1 TN 2013000027A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pyrazol
- oxy
- ethyl
- methyl
- solid forms
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 title 1
- DGPGXHRHNRYVDH-UHFFFAOYSA-N 4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine Chemical compound N=1N(C=2C=C3C=CC=CC3=CC=2)C(C)=CC=1OCCN1CCOCC1 DGPGXHRHNRYVDH-UHFFFAOYSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to solid forms having a low degree of crystallinity or substantially amorphous of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) and processes for their preparation
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/063583 WO2012019984A1 (en) | 2010-08-09 | 2011-08-08 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000027A1 true TN2013000027A1 (en) | 2014-06-25 |
Family
ID=54360739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000027A TN2013000027A1 (en) | 2011-08-08 | 2013-01-28 | - 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2013000027A1 (en) |
-
2013
- 2013-01-28 TN TNP2013000027A patent/TN2013000027A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202105175B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| PH12013500218A1 (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride solid forms | |
| PL2503993T3 (en) | Hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine | |
| HK1218415A1 (en) | Processes for making compounds useful as inhibitors of atr kinase atr | |
| AP3847A (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| ZA201400012B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201308397B (en) | Inhibitors of bruton's tyrosine kinase | |
| IL228967B (en) | Heterocylic compounds as kinase inhibitors | |
| ZA201400739B (en) | Inhibitors of bruton's tyrosine kinase | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| IL231725A0 (en) | Crystalline forms of afatinib di-maleate | |
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| MA33835B1 (en) | 4- [2 - [[5-METHYL-1- (2-NAPHTHALENYL) -1H-PYRAZOL-3-YL] OXY] ETHYL] MORPHOLINE SALTS | |
| EP2736905A4 (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
| HK1182383A1 (en) | Crystalline forms of kinase inhibitors | |
| ZA201105124B (en) | Process for the preparation of rosuvastatin salts | |
| HUP1000638A2 (en) | Process for preparation of rosuvastatin salts | |
| IL231758A0 (en) | Uses of growth and differentiation factor 8 (gdf-8) | |
| TN2013000027A1 (en) | - 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms | |
| HK1182384A1 (en) | Crystalline forms of kinase inhibitors | |
| HK1179255A1 (en) | Crystalline forms of kinase inhibitors | |
| IL229920A (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
| TN2013000035A1 (en) | Highly crystalline valsartan | |
| HUP1000616A2 (en) | Process for preparation of rosuvastatin salt |